Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 15/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18980262 | 0.87 | POLB (0.70) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL4178254 | 0.84 | ALDH1A1 (0.61) | RAB9ASMN1; SMN2NPSR1NPBWR1MAPT | |
| SCHEMBL18980285 | 0.84 | SMN1; SMN2 (0.73) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL18979949 | 0.82 | RAB9A (0.67) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL18979944 | 0.80 | MEN1 (0.63) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL21521858 | 0.77 | NPBWR1 (0.61) | RAB9ASMN1; SMN2NPBWR1PKMPKLR | |
| SCHEMBL18980164 | 0.77 | RAB9A (0.76) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL19000729 | 0.76 | NPBWR1 (0.72) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL17099741 | 0.75 | MEN1 (0.73) | POLBMEN1RAB9ABLMKMT2A | |
| SCHEMBL10642561 | 0.75 | RAB9A (1.00) | POLBMEN1RAB9ABLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | BAK1, DCLRE1B, BLVRB | POLB 11/4885MEN1 4584/4885RAB9A 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.